Skip to content

Case study: Preventing cerebral palsy in babies

The healthcare challenge

One per cent of all births are pre-term (before 30 weeks) – 10 per cent of these babies have cerebral palsy. Although survival rates for premature babies have improved, the number with cerebral palsy continues to increase. Cerebral palsy affects around 2.5 babies per 1,000 a year in the UK – locally, this means 75 babies per year. 

Solution/outcomes to date

Prevention of Cerebral Palsy in PreTerm Labour – or PReCePT, for short – has been developed from a proposal by Dr Karen Luyt, consultant neonatologist at University Hospitals Bristol to increase the use of magnesium sulphate (MgSO4) as a treatment to protect the brain in pre-term babies, ultimately making it a standard practice in local hospitals.

Magnesium sulphate has been proved to reduce the risk of developing cerebral palsy in pre-term babies by around 50 per cent. However, although the cost is only £1 per treatment, only 30 per cent of eligible mothers receive magnesium sulphate. In the UK, if all mothers of at-risk babies could be treated, we could prevent five babies each year from developing cerebral palsy in the West of England alone.

Watch our video to find out more:

Preventing cerebral palsy in preterm labour (PReCePT) from West of England AHSN on Vimeo.

Support from the West of England AHSN

In August 2014, the PReCePT project went live in three trusts: Royal United Hospitals Bath NHS Trust; Gloucestershire Hospitals NHS Trust; and North Bristol NHS Trust. The three Project Midwives leading on the project were charged with developing a baseline audit, developing a training plan and putting in place a timeline for delivery.

Standard patient pathway guidance for the management of suspected pre-term labour has been developed. For clinicians, an information pack has been produced that will enable increased use of magnesium sulphate and support improved data capture on maternity unit databases.

Other materials created include a patient information leaflet detailing when magnesium sulphate may be appropriate as a treatment and a visual prompt for staff to identify patients where the use of magnesium sulphate as a neuroprotector may be appropriate.

For more information, contact Dave Evans at david.evans@weahsn.net.


Twitter

@100k_WEGMC

please respond if you are in primary care and help us ensure that we have appropriate genomics education resources for you…

Favourite | Retweet

@UK_Life_Science

View the #AHSNs impact from 2013 onwards. https://t.co/oQNlH3lKlz https://t.co/jdNbDMdGN3

Favourite | Retweet

@MikeyBUK

•6m patients benefited & £300m investment leveraged to support healthcare & industry. Learn more about #AHSNs impact https:/…

Favourite | Retweet

@weahsn

Join @NHSImprovement's webinar Mon 9:30 with @emmaredfern5 for tips on using the #EDChecklist https://t.co/24xqUnYsvE #AHSNs #wintersafety

Favourite | Retweet